Novartis: 15 Covid-related drugs currently studied
(CercleFinance.com) - At a virtual investor event today, Novartis said it currently has 15 Covid-related drugs being currently studied in 35 clinical trials worldwide.
The Swiss drugmaker said that it has already completed enrollment for a Phase III clinical trial studying immunotherapy canakinumab in patients with Covid-19 pneumonia, with an expected readout in the fourth quarter.
Novartis said it also continues its Phase III clinical trial to evaluate the use of ruxolitinib, a well-established JAK inhibitor, in coronavirus patients with a severe immune reaction.
Simultaneously, Novartis has announced a new collaboration to facilitate the supply of Covid-19 related medicines to the AU member states, representing all the 55 countries on the African continent.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Swiss drugmaker said that it has already completed enrollment for a Phase III clinical trial studying immunotherapy canakinumab in patients with Covid-19 pneumonia, with an expected readout in the fourth quarter.
Novartis said it also continues its Phase III clinical trial to evaluate the use of ruxolitinib, a well-established JAK inhibitor, in coronavirus patients with a severe immune reaction.
Simultaneously, Novartis has announced a new collaboration to facilitate the supply of Covid-19 related medicines to the AU member states, representing all the 55 countries on the African continent.
Copyright (c) 2020 CercleFinance.com. All rights reserved.